by Emily Burke, PhD | Jul 13, 2017 | Metabolic & Cardiovascular Disease
MEDS FOR THINNER BLOOD CAN EQUAL FEWER CLOTS, BUT HOW? The FDA’s recent approval of Portola Pharmaceuticals’ (South San Francisco, CA) new blood thinner drug Bevyxxa paved the way for the prevention of blood clots in patients hospitalized for conditions...
by Emily Burke, PhD | Nov 10, 2016 | Metabolic & Cardiovascular Disease
Targeting Fat Obesity is considered one of the most pressing public health issues of the day. According to the Center for Disease Control, 37% of adults and 17% of children in the U.S. are obese. The latest drug interventions work by attempting to suppress food...
by Emily Burke, PhD | Feb 16, 2016 | Metabolic & Cardiovascular Disease
Identifying Gut Proteins To Tackle Metabolic Disorders Historians of science love to tell about “eureka moments”—simple observations leading to major insight. Greek mathematician Archimedes allegedly exclaimed the original “Eureka!”—meaning “I have found it!”—upon...
by Emily Burke, PhD | Jun 25, 2015 | Metabolic & Cardiovascular Disease
$23 Billion Blockbuster? The PCSK9 inhibitor buzz keeps rolling, especially since sitting before the FDA Advisory Committee earlier this month. Amgen’s (Thousand Oaks, CA) Repatha and Sanofi’s (Paris, France) Praluent are a new class of cholesterol lowing...
by Emily Burke, PhD | May 26, 2015 | Metabolic & Cardiovascular Disease
The Race Against Nash A silent epidemic creeping upon the Western world pushed the headline grabbing acquisition of a Phase 1 non-alcoholic steatohepatitis (NASH) drug last week. Boehringer Ingelheim (Ingelheim, Germany) acquired Pharmaxis (Sydney, Autralia) due to...
by Emily Burke, PhD | Sep 11, 2014 | Metabolic & Cardiovascular Disease
In a picture perfect game of drug development, Novartis heartily delivered this week with LCZ696. Also propelling the world of cardiovascular disease treatments into high gear is a promising cholesterol therapeutic by Sanofi and Regeneron called alirocumab. Last week,...
